Your session is about to expire
← Back to Search
PSB202 for B-Cell Lymphoma
Study Summary
This trial is testing a new two-part drug called PSB202 to see if it is safe and effective in treating patients with B-cell malignancies.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Patients can continue certain standard cancer treatments, like hormone therapy for breast and prostate cancer, and growth factor support after a certain period.You must have stopped taking any anti-CD20 antibody therapy at least 4 weeks before starting PSB202.If you had COVID-19 within 6 months before you join the study, you need to get tested again to make sure you don't have it when you join.You must be at least 18 years old to participate, and there is no maximum age limit.You have a history of pneumonitis or interstitial lung disease.You have a history of liver damage caused by medication or cirrhosis.You have a certain type of non-Hodgkin lymphoma, chronic lymphocytic leukemia, or Waldenström macroglobulinemia that has not responded to or cannot tolerate standard treatments.You have a condition where your immune system attacks your own blood cells, like autoimmune hemolytic anemia or idiopathic thrombocytopenic purpura.You have received radiation treatment within 7 days before starting the study, except for some specific types of radiation treatments.People who have HIV are not allowed to participate because the study drug might interact with their HIV medications and increase the risk of infections. If you don't know if you have HIV, you will be tested before joining the study.You have tried at least two standard treatments, but your disease has continued to get worse.You are able to perform everyday activities without assistance or with some restrictions.You have a serious, uncontrolled infection or other active disease that makes it not safe for you to be part of the trial.You have had a stem cell transplant or CAR-T therapy in the last six months and still have certain related health issues or are taking certain medications.Only patients with a large mass (10 cm or larger) due to non-Hodgkin's lymphoma can participate in the dose escalation phase.You had a major surgery within 4 weeks before the study starts.You currently have graft versus host disease (GVHD) or are taking medication to suppress your immune system.You have had a stem cell transplant from a donor or a special type of immune cell therapy called CAR-T in the past.If you have a specific type of advanced blood cancer, you cannot be in the first phase of the trial, and you cannot be taking any other experimental treatments at the same time.You must wait at least four weeks after any previous cancer treatment before joining the study, unless your doctor approves a shorter wait because of potential health risks.You have sufficient blood and clotting abilities before starting treatment.Your liver is working properly.You have active hepatitis B or C, as shown by positive blood tests, or need treatment for it. If you have a history of hepatitis C and have been successfully treated, you can still participate.You have an ongoing autoimmune disease or have been treated for an autoimmune disease within the last 2 years, except for certain conditions like hypothyroidism and vitiligo. If you had childhood asthma or atopy, it should not have been active in the 2 years before the study screening.You have tried at least two standard treatments that did not work for your condition, and if you have follicular lymphoma, you must have been treated with at least one regimen containing rituximab.Your kidneys are working well, with a filtration rate of at least 50 mL per minute.You have been diagnosed with a certain type of cancer that has a specific protein called CD20. If the cancer has CD37 protein, a blood test may be needed to confirm it after you join the study.You are still experiencing side effects from your previous treatment that are greater than a Grade 2 except for hair loss.You have lymphoma that has spread to your central nervous system, unless you have received treatment for it and are stable without any signs of active disease, with approval from the study sponsor.You have had a stroke, heart attack, or severe heart failure in the past 6 months, or your heart's electrical activity is abnormal.People with specific types of slow-growing lymphomas who have not responded well to at least two standard treatments can participate. If you have follicular lymphoma, you must have been treated with rituximab before. If you have mantle cell lymphoma, you must have received a certain type of medication before.
- Group 1: Single-arm, escalating dose levels
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Can PSB202 be reliably consumed without adverse effects?
"Due to the early phase of clinical trials, PSB202 was assigned a score of 1 with regards to safety. Thus far there is only limited data supporting its efficacy and any potential harms."
What aims does this clinical experiment endeavor to attain?
"According to the trial's sponsor, Qilu Puget Sound Biotherapeutics (dba Sound Biologics), Adverse Events are the primary outcomes being monitored over a three-week period. Additionally, secondary objectives like International Working Group Criteria for NHL and Hallek Criteria for CLL will be assessed along with Plasma Concentration versus Time Curve AUCs and Peak Plasma Concentrations of PSB202 components PSB102 and PSB107."
What is the total enrollment capacity for this research initiative?
"True, the clinicaltrial.gov listing confirms that recruitment is presently underway for this trial which was originally posted on November 15th 2021 and updated most recently on March 11th 2022. The investigators need to recruit a total of 110 individuals across two sites."
Are there still opportunities for potential participants to join this research endeavor?
"As per the clinicaltrials.gov post, this trial is presently in search of test subjects. It was first made available to the public on November 15th 2021 and has been recently updated 11 March 2022."
Share this study with friends
Copy Link
Messenger